Palisade Bio (PALI) Competitors $1.01 -0.01 (-0.98%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.00 -0.01 (-0.99%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PALI vs. CYCC, BCAB, RLMD, PASG, CASI, CMMB, FNCH, RLYB, SYBX, and LPCNShould you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Cyclacel Pharmaceuticals (CYCC), BioAtla (BCAB), Relmada Therapeutics (RLMD), Passage Bio (PASG), CASI Pharmaceuticals (CASI), Chemomab Therapeutics (CMMB), Finch Therapeutics Group (FNCH), Rallybio (RLYB), Synlogic (SYBX), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. Palisade Bio vs. Its Competitors Cyclacel Pharmaceuticals BioAtla Relmada Therapeutics Passage Bio CASI Pharmaceuticals Chemomab Therapeutics Finch Therapeutics Group Rallybio Synlogic Lipocine Cyclacel Pharmaceuticals (NASDAQ:CYCC) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations. Do analysts recommend CYCC or PALI? Palisade Bio has a consensus target price of $12.00, indicating a potential upside of 1,088.12%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than Cyclacel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Palisade Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer CYCC or PALI? In the previous week, Palisade Bio had 1 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 2 mentions for Palisade Bio and 1 mentions for Cyclacel Pharmaceuticals. Palisade Bio's average media sentiment score of 0.47 beat Cyclacel Pharmaceuticals' score of -1.00 indicating that Palisade Bio is being referred to more favorably in the news media. Company Overall Sentiment Cyclacel Pharmaceuticals Negative Palisade Bio Neutral Which has more risk and volatility, CYCC or PALI? Cyclacel Pharmaceuticals has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Is CYCC or PALI more profitable? Palisade Bio's return on equity of -178.96% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cyclacel PharmaceuticalsN/A -3,648.09% -155.99% Palisade Bio N/A -178.96%-127.35% Which has higher earnings and valuation, CYCC or PALI? Cyclacel Pharmaceuticals has higher earnings, but lower revenue than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclacel Pharmaceuticals$14K1,100.44-$11.21M-$839.58-0.01Palisade Bio$250K19.39-$14.44M-$6.80-0.15 Do insiders & institutionals believe in CYCC or PALI? 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are owned by company insiders. Comparatively, 3.3% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryPalisade Bio beats Cyclacel Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PALI vs. The Competition Export to ExcelMetricPalisade BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.89M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-0.1517.6228.6723.80Price / Sales19.39179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book0.378.508.275.55Net Income-$14.44M-$55.06M$3.24B$259.03M7 Day Performance-12.93%-3.98%-3.69%-4.59%1 Month Performance38.45%9.59%4.33%4.46%1 Year Performance-72.48%6.72%25.95%18.03% Palisade Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PALIPalisade Bio2.7055 of 5 stars$1.01-1.0%$12.00+1,088.1%-72.3%$4.89M$250K-0.1510CYCCCyclacel Pharmaceuticals0.1891 of 5 stars$13.49-12.4%N/A-97.6%$21.53M$40K-0.0214Negative NewsShort Interest ↑Gap DownBCABBioAtla2.0695 of 5 stars$0.37+4.2%$5.00+1,255.0%-81.1%$21.50M$11M-0.3060Upcoming EarningsRLMDRelmada Therapeutics4.4511 of 5 stars$0.64+0.2%$5.00+678.8%-84.0%$21.31MN/A-0.2610News CoverageUpcoming EarningsPASGPassage Bio3.83 of 5 stars$6.82-3.3%$150.00+2,101.0%-69.8%$21.15MN/A-0.33130Gap DownCASICASI Pharmaceuticals3.9578 of 5 stars$1.71+5.2%$4.00+134.6%-81.7%$20.97M$28.54M-0.67180Positive NewsGap UpCMMBChemomab Therapeutics2.9335 of 5 stars$1.10+0.8%$8.50+673.4%-11.6%$20.73MN/A-1.4520Positive NewsFNCHFinch Therapeutics GroupN/A$12.50-0.4%N/A+556.3%$20.08MN/A-1.42190RLYBRallybio1.8052 of 5 stars$0.48-5.7%$10.00+2,005.3%-59.5%$19.77M$640K-0.4440Short Interest ↑SYBXSynlogic1.0079 of 5 stars$1.62-0.3%N/A-14.0%$18.90M$10K-0.6480Upcoming EarningsLPCNLipocine2.6175 of 5 stars$3.34-1.7%$9.00+169.4%-38.0%$17.97M$11.20M-3.2910Upcoming Earnings Related Companies and Tools Related Companies CYCC Alternatives BCAB Alternatives RLMD Alternatives PASG Alternatives CASI Alternatives CMMB Alternatives FNCH Alternatives RLYB Alternatives SYBX Alternatives LPCN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PALI) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
